Overview

• Effective Oct. 1, branded or patented drug imports face a 100% tariff unless the manufacturer is “building” a U.S. plant, defined as breaking ground or under construction.
• New import levies also include a 25% tariff on heavy trucks, 50% on kitchen cabinets and bathroom vanities, and 30% on upholstered furniture.
• Asian and Indian pharma shares fell after the announcement, with India’s Nifty Pharma index down more than 2% in early trading.
• India, a key supplier to the U.S., risks revenue pressure as several major firms derive 30–50% of sales from America and exported roughly $3.6 billion in 2024 and $3.7 billion in the first half of 2025.
• The move relies on Section 232 national-security authority, and analysts note unresolved questions on whether generics, complex products or APIs could be drawn in, as well as potential cost impacts for U.S. payers including Medicare and Medicaid.